In this study, the pancancer analysis of NR2F6 found that NR2F6 appeared as a tumor-promoting factor in various tumor types, and its expression was closely associated with patient prognosis, and higher expression was associated with reduced survival time. This evidence concerns the gene NR2F6 and neoplasm.